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Background: MLK3 gene mutations were described to occur in about 20% of microsatellite unstable
gastrointestinal cancers and to harbor oncogenic activity. In particular, mutation P252H, located in the kinase
domain, was found to have a strong transforming potential, and to promote the growth of highly invasive tumors
when subcutaneously injected in nude mice. Nevertheless, the molecular mechanism underlying the oncogenic
activity of P252H mutant remained elusive.
Methods: In this work, we performed Illumina Whole Genome arrays on three biological replicas of human HEK293
cells stably transfected with the wild-type MLK3, the P252H mutation and with the empty vector (Mock) in order to
identify the putative signaling pathways associated with P252H mutation.
Results: Our microarray results showed that mutant MLK3 deregulates several important colorectal cancer- associ-
ated signaling pathways such as WNT, MAPK, NOTCH, TGF-beta and p53, helping to narrow down the number of
potential MLK3 targets responsible for its oncogenic effects. A more detailed analysis of the alterations affecting the
WNT signaling pathway revealed a down-regulation of molecules involved in the canonical pathway, such as DVL2,
LEF1, CCND1 and c-Myc, and an up-regulation of DKK, a well-known negative regulator of canonical WNT signaling,
in MLK3 mutant cells. Additionally, FZD6 and FZD10 genes, known to act as negative regulators of the canonical
WNT signaling cascade and as positive regulators of the planar cell polarity (PCP) pathway, a non-canonic WNT
pathway, were found to be up-regulated in P252H cells.
Conclusion: The results provide an overall view of the expression profile associated with mutant MLK3, and they
support the functional role of mutant MLK3 by showing a deregulation of several signaling pathways known to
play important roles in the development and progression of colorectal cancer. The results also suggest that mutant
MLK3 may be a novel modulator of WNT signaling, and pinpoint the activation of PCP pathway as a possible
mechanism underlying the invasive potential of MLK3 mutant cells.
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Mixed-lineage kinase 3 (MLK3) belongs to a family of
seven different mammalian MLKs, that are clustered in
three subgroups accordingly with their structural simi-
larities: the MLKs (MLK1, MLK2, MLK3, MLK4); the
dual-leucine-zipper-bearing kinases (Dlk and Lzk); and
zipper sterile-α-motif kinase (Zakα and Zakβ) [1].
MLK3 protein is composed by a Src-homology-3 (SH3)
domain, located at the amino terminus of the protein,* Correspondence: rseruca@ipatimup.pt
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Cdc42/RAC interacting binding motif (CRIB) and a
Proline/Serine/Threonine-rich (P/S/T-rich) carboxy termi-
nal domain [1-4]. All these domains show a very high de-
gree of homology between MLK members (MLK1-MLK4)
[1], except the carboxy-terminus P/S/T- rich domain which
is the less conserved region among MLK proteins [1].
MLK3 is a serine/threonine protein kinase that regu-
lates the mitogen-activated protein kinase (MAPK)
pathway, activating ERK, p38 and JNK in response
to extracellular signals [1,5]. Additionally, functional
studies have demonstrated that overexpression of wild-
type MLK3 leads to morphological transformation oftd. This is an Open Access article distributed under the terms of the Creative
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that is MEK/ERK dependent [6]. Further, MLK3 has
been demonstrated to function as a scaffolding protein,
involved in the formation of a multiprotein complex
containing MLK3/BRAF/RAF1 [1,5,7,8]. The forma-
tion of this complex was shown to be important for the
activation of wild-type BRAF and, consequently, to
the activation of ERK signaling [1,5,7,8]. Furthermore,
MLK3 was reported to be important for the prolifera-
tion of tumor cells, bearing either oncogenic KRAS or
neurofibromatosis-1 (NF1) or NF2 inactivating muta-
tions [8]. In addition, the MLK3 signaling activation
was associated with an increase in the migratory and
invasive capacity of tumor cells in gastric [9], breast
[10-12], lung [13] and ovarian [14] cancers. All to-
gether, these observations implicate MLK3 as a cancer-
related gene although, until recently, nothing was
known about MLK3 gene deregulation in primary can-
cer tissues.
Our group reported the occurrence of MLK3 mutations
in microsatellite unstable (MSI) gastrointestinal tumors
(both sporadic and hereditary forms) in a frequency of
about 20%. Using in vitro transforming assays, we demon-
strated that several MLK3 mutations affecting different do-
mains of the protein had transforming potential when
compared to cells expressing the wild-type and the kinase-
dead forms of the protein [15]. These results were further
supported by in vivo studies in which one of the two most
transforming mutations (P252H – located in the kinase do-
main) was found to be tumorigenic and to give rise to
highly invasive tumors when subcutaneously injected in
nude mice. Thus, our previous work pointed mutant
MLK3 as a new oncogene in MSI gastrointestinal cancers,
however, the signaling pathways associated to its oncogenic
activity remained to be explored.
In this work, we aimed at identifying the signaling path-
ways associated to mutant MLK3, in particular the P252H
mutation. The reasons underlying the choice for this muta-
tion were: (a) it was one of the most transforming mutations
previously analyzed; (b) showed high tumorigenic capacity
with strong invasive potential in in vivo studies; and (c) it
was located in the kinase domain which is an important do-
main for the regulation of downstream signaling pathways.
The results showed that P252H mutation interferes with
important colorectal cancer-associated signaling pathways
such as WNT, MAPK, NOTCH, TGF-β and P53.
Methods
cDNA constructs and mutagenesis
Wild-type MLK3 and mutant sequences were cloned
into pLENTID6/V5 directional TOPO (Invitrogen). Mutant
MLK3 P252H sequence was generated by site-directed mu-
tagenesis using the MLK3 wild-type sequence cloned in
pLENTID6/V5 as template. pLENTID6/V5 empty vector(Mock) was obtained by the insertion of a small fragment
of cDNA in order to circularize the plasmid.
Cell lines
Human HEK293 were maintained in DMEM (Gibco,
Invitrogen) supplemented with 10% FBS and 1% peni-
cillin–streptomycin (Gibco, Invitrogen), and were in-
cubated in a humidified chamber with 5% CO2 at 37°C.
Transfections
For HEK293 stable transfections, ViraPower Lentiviral
Expression kit (Invitrogen) was used for the transduction
of the MLK3 wild-type and mutant P252H sequences
as well as the empty vector. Lentiviral transduction
was performed following the manufacturer’s instructions.
Transduced cells were selected by antibiotic resistance
(blasticidin, 12 μg/ml) (Gibco, Invitrogen). The expres-
sion levels of MLK3 in the different clones selected were
measured by western-blot.
RNA extraction and cDNA synthesis
Total RNA was isolated from cell lines using TriPure
Isolation Reagent (Roche Applied Science), following
manufacturer’s instructions. Complementary DNA was
synthesized from 1 μg of total RNA using SuperScriptII
Reverse Transcriptase (Invitrogen) and Random Primers
(Invitrogen).
Labeling and hybridization
Five hundred ng aliquots of RNA from the samples were
quality checked using the Agilent 2100 Byoanalyzer and
only samples above integrity quality number (RIN) 8
[16] were used and amplified according to the specifica-
tions of the Illumina® TotalPrep™ RNA Amplification Kit
(Ambion, Austin, TX, USA). The cRNA samples were
applied to the arrays of Sentrix® Human-v6 Expression
BeadChip (Illumina, San Diego, CA, USA) and hybridized
according to manufacturer's specifications. The Sentrix
BeadChips were scanned with the Illumina's Beadarray
system 500G Scanner (Illumina®).
Microarray data analysis
The signal intensity was extracted from the hybridization
images, background subtracted and normalized using
Illumina Inc. BeadStudio software version 3.3.7. The
data produced was checked against the Illumina internal
quality controls and loaded into the Bioconductor soft-
ware [17,18]. To identify differentially expressed genes
based on a moderate t-test, the bioconductor Limma
package [19] was used. Genes were selected based on a
p-value cut-off (after adjustment) of p < 0.01 to control the
false discovery rate (FDR) [20]. To test the association of se-
lected differentially expressed genes with KEGG pathways
[21], information provided in the Illumina annotation files
Figure 1 (See legend on next page.)
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Figure 1 Expression profiling of biological triplicates of HEK293 cells transfected with mutant and wild-type MLK3. (a) Heatmap of the
445 genes which clearly classify the mutant vs the wild-type, selected on the basis of a 2 log-fold change in expression between cells transfected
with P252H mutant and wild-type forms of MLK3, and eliminating genes which were differentially expressed between the Mock and wild-type
transfection (red=down-regulated in P252H mutant MLK3, green=up-regulated in P252H mutant MLK3). (b) Illustrates a subset of the
heatmap, focusing on genes which are part of the colorectal cancer pathway which is significantly affected (p-value = 0.03). (c) Graphical
representation of the colorectal pathway (larger rounded rectangle) and relevant pathways contained within it (smaller rounded rectangles),
such as MAPK, WNT, TGF-β, NOTCH and p53, indicating differentially expressed genes (ovals) present in Figure 1, their relationships to each
other (solid line indicates a direct protein-protein interaction, T shaped ending for inhibition interactions, arrow ending for activation
interactions, and no ending for other known interactions), as well as the direction of the expression change (red = down-regulated in P252H
mutant MLK3 transfection, green = up-regulated in mutant MLK3). White Diamond shaped boxes indicate entire gene families, which are
significantly affected, genes within the families are shown as colored ovals. Long dashed lines indicate genes, which are present in multiple
pathways. (d) Graphical representation of Real-time PCR quantification of mutant vs wild-type MLK3 targets (LEF1, CCND1, BMP6 and
FZD10) selected from expression microarrays.
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test available in the GOstats packages [22] was used. A
p-value cut off of 0.05 was considered. Microarray data can
be found at the GEO repository with the accession number
GSE54611.
Real-time PCR
One μl of cDNA was added to 10 μl Real-Time PCR
mixtures containing 1x TaqMan® Universal PCR Master
Mix, No AmpErase® UNG (Applied Biosystems) and
1x TaqMan® MGB specific probes and primers mix.
Taqman expression assays for BMP6 (Hs01099594_
m1), CCND1 (Hs00277039_m1), FZD10 (Hs00273077_
s1), LEF1 (Hs00212390_m1) were purchased from
Applied Biosystems. The eukaryotic 18S rRNA assay
(Hs99999901_s1; Applied Biosystems) was used as an
endogenous control gene. Standard TaqMan thermocy-
cling conditions were used: 1 cycle of 2 minutes atTable 1 KEGG Pathways significantly affected by mutant MLK
KEGG p-value Odds Exp count Count
ID Ratio
970 0.000 4.669 5 16
290 0.001 7.682 2 7
5120 0.001 2.477 11 21
251 0.004 3.184 5 11
630 0.009 4.693 2 6
4115 0.013 1.984 11 18
330 0.014 2.517 5 11
3020 0.018 2.923 4 8
5020 0.026 2.948 3 7
670 0.027 3.283 2 6
5210 0.03 1.721 13 20
600 0.031 2.155 6 11
260 0.038 1.995 7 12
5040 0.041 2.241 5 9
5110 0.044 2.01 6 1150°C, 1 cycle of 10 minutes at 95°C, 40 cycles of 15 sec-
onds at 95°C followed by 1 minute at 60°C in an ABI
Prism 7000 (Applied Biosystyems). Real-Time PCR
assays (absolute quantification) were performed in, at
least, three biological replicas.
Statistical analyses
For statistical analyzes of in vitro transformation assays
a t-student test was used and p < 0.05 was taken as sta-
tistically significant. Specific statistical tests used for
microarray interpretation are embedded in the corre-
sponding materials and methods section.
Results and discussion
MLK3 P252H mutation affects fundamental colorectal
cancer-associated pathways
In order to assess the effect of a tumorigenic MLK3 mutant
on a genome-wide level, we performed microarray-based3
Size Term
35 Aminoacyl-tRNA biosynthesis
12 Valine, leucine and isoleucine biosynthesis
68 Epithelial cell signaling in Helicobacter pylori infection
30 Glutamate metabolism
13 Glyoxylate and dicarboxylate metabolism
68 p53 signaling pathway
35 Arginine and proline metabolism
23 RNA polymerase
20 Parkinson's disease
16 One carbon pool by folate
84 Colorectal cancer
39 Sphingolipid metabolism
45 Glycine, serine and threonine metabolism
31 Huntington's disease
41 Cholera - infection
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Genome arrays on three biological replicas of human
HEK293 cells stably transfected with the wild-type MLK3,
with the MLK3 P252H mutation and with the empty vector
(Mock). The expression profiles were obtained by compar-
ing all biological replicas from each transfection experi-
ment. Colorectal cancer cell lines were not used in this
experiment, as proteins from the MAPK pathway are fre-
quent mutation targets in this type of cancer, and would
most likely interfere with the interpretation of the results.
The expression profiles were compared to identify genes
that were differentially expressed at least 2 log-fold (FDR <
0.01) between wild-type and Mock, as well as between
P252H and Mock. A final set of 445 genes was identified
which showed significant differential expression only be-
tween P252H and wild-type and not between wild-type and
Mock (Figure 1a). The most statistically significantly differ-
entially expressed genes are displayed in Figure 1b. The
genes identified were significantly enriched (p < 0.05)
in several KEGG pathways (Table 1) involved in overall
biosynthesis processes, as well as in response in disease
relevant processes. Interestingly, the colorectal path-
way, which encompasses several relevant pathways
such as WNT, MAPK, NOTCH, TGF-β and P53,
was significantly over-represented (Figure 1c). These
signaling pathways are crucial to maintain intestinal
epithelium homeostasis by balancing the rate of prolifera-
tion, apoptosis, and differentiation along the crypt-villus
axis, and their de-regulation is commonly associated to
colorectal cancer initiation and progression [23]. Corrobor-
ating our results, a recent study using both in vivo and
in vitro approaches showed that MLK3 signaling is import-
ant in intestinal mucosal healing and epithelial cell motility
[24], therefore implicating MLK3 signaling in the mainten-
ance of intestinal epithelial homeostasis.
In order to further validate the microarray data, a set
of differentially expressed genes (LEF1, CCND1, FZD10,
and BMP6) were selected for validation by real-time
PCR in HEK293 cells stably expressing MLK3 wild-type
or MLK3 P252H. The results obtained with the microar-
rays were validated for all genes tested (Figure 1d).
Of particular interest are the alterations that mutant
MLK3 induces in the WNT pathway. Activation of ca-
nonical WNT signaling through WNT/β-catenin cascade
has traditionally been regarded as a critical player in
colorectal tumorigenesis [25]. More recently, accumu-
lating evidence supports a role for the non-canonical
WNT planar cell polarity (PCP) pathway, a signaling
cascade involved in the polarization of cells during tis-
sue remodeling, and cell adhesion and motility, in can-
cer progression, invasion, metastasis, and angiogenesis
[26-28]. A more detailed analyzes of our microarray
data showed that the expression of several molecular
components of the canonical pathway, such as DVL2,LEF1, CCND1 and c-MYC were down-regulated in
MLK3 mutant cells, and the expression of DKK, a well-
known negative regulator of canonical WNT signaling
[29], was up-regulated (Figure 1c and d). On the other
hand, genes encoding two WNT receptors known to act as
negative regulators of the canonical WNT/β-catenin signal-
ing cascade and as positive regulators of the PCP pathway,
FZD6 and FZD10, were found to be up-regulated in P252H
cells (Figure 1c and d). Taken together, the down-regulation
of DVL2, LEF1, CCND1 and c-MYC, and the up-regulation
of DKK and FZD receptors suggest a role of mutant MLK3
as a molecular switch between canonic and non-canonic
WNT signaling. In accordance, it was recently reported that
MLK3 reduces the expression of β-catenin/TCF down-
stream targets by promoting the interaction between β-
catenin and KLF4, a known repressor of β-catenin/TCF
transcriptional activity [30]. Furthermore, in accordance
with a role of PCP in colorectal cancer, FZD10 was
recently demonstrated to be up-regulated in colorectal
cancers and matched liver metastases, and its over-
expression was associated with the activation of non-
canonical WNT pathway [31,32].Conclusion
In conclusion, our results provide an overall view of
the expression profile associated with mutant MLK3,
and they support the functional role of mutant MLK3
by showing a deregulation of several signaling path-
ways known to play important roles in the develop-
ment and progression of colorectal cancer. The results
also suggest that mutant MLK3 may be a novel modu-
lator of WNT signaling, and pinpoint the activation of
the PCP pathway as a possible mechanism underlying
the invasive potential of MLK3 mutant cells. Neverthe-
less, further studies are required in order to validate
this hypothesis in a panel of gastrointestinal cell lines
and human primary tumors, to determine if the altered
signaling pathways are common to other MLK3 muta-
tions, and to investigate the role of mutant MLK3 in
the context of mutant KRAS and BRAF genes.
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